Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has issued an update.
Hangzhou Tigermed Consulting has issued an unaudited estimate for its 2025 full-year results, projecting net profit attributable to shareholders of RMB830 million to RMB1.23 billion, representing a year-on-year increase of 105% to 204%, on expected operating revenue of RMB6.66 billion to RMB7.68 billion, up 1% to 16%. The sharp improvement in headline earnings is largely driven by a swing in non-recurring items, with non-recurring gains and losses attributable to shareholders estimated at RMB500 million to RMB740 million versus a negative RMB449.8 million a year earlier, while underlying net profit after excluding non-recurring items is expected to drop 43% to 61%, underscoring pressure on core profitability despite stable cash flow from operations and an anticipated rise in basic earnings per share to RMB0.96–1.43.
The most recent analyst rating on (HK:3347) stock is a Hold with a HK$54.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-based contract research organization (CRO) operating in the pharmaceutical and life sciences industry, providing clinical trial and related R&D services to drug and medical device developers, with a market focus on both domestic and international biopharma clients.
Average Trading Volume: 2,196,003
Technical Sentiment Signal: Buy
Current Market Cap: HK$51.25B
Find detailed analytics on 3347 stock on TipRanks’ Stock Analysis page.